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[ uring the llrst 2() years of the I'l'nicillin erJ there were
relanvely ft'w 13-bctal1lases. Pcnicillinase-produ ing taphylo-
COCCI remtal1t to peniCillin G were a serious problem in nearly
all ho. pltals. WIlh rill' advl'nt of the senusynthetic penicillins
the prohlcm ahated. This led then to the CrJ ofhroad-spectrum
penici.lIins and 'l'l'halosporins when Gram-negatIve bacilli
b'Tt'w in clinical importance and lht' 13-la tama e. of Gralll-
ncg;ltiw bacilli becamc an Import. m resisrance lllechanism.
For the 6 t 25 years tht' number of dif}crenl 13-1actama es
remaim'd linuted r11. Most of the ,r:ull-negatIV(' bacIlli had a
TEM-I 13-1:1 t.ma.e and Klebsiella had an 'HV-t. lodecrric
Table 1 Approval dates of fJ.laclam antib,o\lcs In the USA
Ii cu ing and kineti ~rudies on extracts from hundreds of
isolates pr dueing the e 13-lactamases showed no hanges.
Then, sudden.ly around I 78 or 19 0, there was a grear
proliferation of many different 13-Jactamase , Coiocldmg with
the c1ini al use of numerous novel 13-lactams. many derived
not from fungi, but from soil bacteria. Thcse novel 13-lact3nl~
(cephamy ins, carbapenems, sul[oncs, Ulan bacrams) are
probably evolutionanly much older tlun tile perucillins and
the cephalosporil1..~ [II. Tabl ... 1 show ti,e d:ues when the Food
and Drug Adrnll1lstrJtlon 111 the U A approved tlllfcrenr l}-
lacrams r. r clinical usc. Penicillin G amved in 1945, the
Antibiotic erB
1940-60. Th penocillin ,a
1960-78 The era of broad-spectrum
penicilions And early cephalosporll1s
1978-current. The era of cephamycll1s.
oXYlminocephaloSpOrtns. monobactams.
carbapenems, and II-Iactamase II1hib,lOrS
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pelllcillina. c-resl c. III sellli~)'l1chetlc pen.lcillms nd first gen-
crJtlon ephalosporins 15-2tl years later; then nound IlJ7R, a
plethora of novel ~-lacr.:lIl1.S began to be used_ When thiS greac
vanety of novel 13-la tams was unleashed on ti,e nucroblal
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populauon. hurst 0 evolutionary change occmed a1110ng p-
bctamases. mggesnve of puncnlated ev lucian 121. nc of the
1Il0$! Illfcrt'Sring exal1lpk'~ w, the elllcrgcn c f extcnder!
pcetrum p-Iactama! eS (ESBLs).
EXTENDED·SPECTRUM j}lACTAMASES
MUI.:1II of che well-c t.1bhshed TEM and HV r~-lacral1lase~
:lP; ble f hydrolyzmg oX)'lInino f}-L1CCln1S were first detccted III
,emuny in I HZ 13J; aCtually a Llt 'r publi ti n do lllllcnted tim
they were ill Argenrma a year before 14J. The TEM and HV P-
laccam~ sh wed no signs of hangc fc rover 30 yl:ars, but 1I0W
owr 75 TEM and 20 SHY mutant j).-laccamascs are recognizt'd.
and Uletr nlunbt:r continues t grow. Thc tertiary ~tnlc[Un.. of
SHY is practically mperimpos,lble on tim of TEM-I, despite
reLlcivcly little sequence siluiliuiry bctween me twO enzymes [5].
Ho picaJ outbreaks duc 10 ESllLs have occured in many
coumnes: onc of the clearest exampJe.s f an outbreak was at
ranford Cluldren's Hospital A study done at the Naoonal
Institutes of HI-aJth showed that it w!t~ not lIec~'$;lry to U$e
plperacJllin + gcnrami .n 10 treal neutropenic children, a.~
cefra1.ldin·w alone worked as well. S ranford ChiJdrcl1S'
Hospiral adopte I cefuzidime as , SlllglC drug of choice or
treating febrile ncutropeni childrcn in 1988 [61, However, they
began 10 isohte Klebsiflln Imellll/Ol/irJf and EsdU'n'c!lin coli resistant 10
ceftazidum', whJch produced a 11 m: nr EM f}-bctamasc, TEM-
26, an ESDL. The same pro c:ss was rcpcated a few years I.1ter in
IE· SI
IE-I')
tile Pediatric neology Unit of St. Jame Universiry Hospiral in
Lt:cd~ in tl1c UK 17J. Several pacien a luircd a K. 1.lII1'IIII/Ql/ine
strain prochl ing a TEM-12 1>-1..1 ram se and many ther.; wcn:
infected with another strain, producing TEM-26 f3-bcralllas '.
nl: might have postulated that this w, gl bal spread: perhaps
a house offi er in Stanlord went to Lced5 t n. in and brought
the stJ<,in w1th him. This was not tl1<' case. When dle complete
sequcl1ce of the TEM-26 I11Ut.ll1lS (rol11 eeds wa~ delermincd,
a number of. minD acids Dues-ide Ihe aC[ivc Ite lilfered Jr III
tb" t.1Jlford TEM-26 mut ntl.. This was eviden 'C of de novo
devdopment f resistauce, in eflecI convergent cv Jution
re ultiJlg from a similar scleni n pressure.
Ho\ do dle bacteria do dus? 1..:Iow are tlley so readily able
to II1Ut.ltC to produce twO different type' lf E BLs? The
IIlslght ha c me frOIl1 thc work of ry~t."lllogr.lphers,
genetici t.'> and biochcmi lS [R-l J]. Bush od Sykes (Figure
I) have poimed our a couplt: of key features of the proce s
1111: p-Iactamase i a protein, a large l110l cule of molccular
weIght about 30000, whIle penicillin IS a much smaller
molenlle wllh a molecular weighl ofabom 30! . Thc penicillin
molt ule has I fit inro mc p-Iacrama e, tive icc. If Il is 100
large It will n t cmer. Then it IllUst bind to the a rive itt:, a
pro t: s not unlike • p. tienl bcmg ~trappcd Onto the
lIeuro. urgeon's operating table. The patient must sla
motionless < the surgeon perfoffi"l$ brain urgery. The
strapping consists of hydr gen bonding berween hydrox)'1
and am.ine groups. When the p-Iactam moleculc i.. bound
Figure 1 Canoon showing entry of II II·
lactam l110lecule llUCl,~~ aCI/ve sl! cavity of
II ~·lactol11ose. hydro1!(s s of the 1l.lactom
ring and release of tho inactiv lod II-Jectam
(from (11)).
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Figure 2 Space I1lIlI1g model 01 the aCllve sue
cavity of S SUlCUS PCl 11·lactamase (Irom [12]).
Figure 3 Ribbon dmgram 01 the TEM·' fl-
lactamase (provldod by Jim Knox. Irom [1) )
lightly. su~ry CJll proceed efficlcntly. i,e. tlw p-lan:ull hond is
spin. mactlvJtll1g dlC ~Iactam, Fi{:\lre 2 sho\ the actJve site caVIty
of Sr 'ph)'IoI:cxrus amn'" ll-lactalllilSC :lnd the actJw site serine (an
orange: hall). dle IIrgeon If yOIl WIll. del'p witlun the aVlry 1121,
The COIllOU. )f the: cavIty are Vl'l IIllpOrtalll nl
dctt'mulling wht,ther the: p-Ia ·tam will fir. Fl~urt' 3 ~hl)\vS
the: ,tl'ucmre of the TEM P-l. talllaSt', At the e:l1tran c t< the
anlve Site 'avlty there IS a stnn" of amino aCid" that foml a
loop. the so- ailed ome:ga loop, whi h linut.'i the SIll: of the
cavlry, Molecules that have bIg 'Idc--:hallls Imply callnot fir.
That. III effeer, is \ h cdot.1xnne and other oxytlTuno P-
lacralll are not lIlacn att'd b Isolates dut produce TEM-I,
Flgllre: -1(A) illu trates imporulll fcalure. of the active site of
TEM-1. H ighl y 'onserved amino aid, 111 the so-c:illcd anion
pocket po. ess hydroxyl and a11IHll' groups that hold U1C P-
Iaetam in place. he scrinc-70 rcsldu .... whICh will pertonn th ...
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Fig 4 (A) SChematic diagram showing the
hydrogen bonding nelwork and the amino
acid residues of the binding site motifs of a
class A p·lactamase. NOle lhe importance 01
residues E166 and N1 70 of Ihe omega loop
In posilloning a waler molecule close 10
serine· 70. (B) Hydrogen bond inleracllons
belween the functional groups at a cepha-
losporm molecule and the side-chains of
tho amino acid residues of the oClive sileo
Note that the NH groups of S70 and A237
hold the carbonyl of the p-/aclam ring in the
oxyanion pocket The side·chains of S130
and T235 enchor one end of Ihe molecule




urgery. is close to w~ter molecule that will provide
hydrogen and a hydrox:yl to add to the ends f the p-lact..111l
bond when it is pulled apa.rt. The omega loop is depicted as a
curved line. Recall that when thO I P is rigid and tight,
cefocaxime will not fit. Figure 4(B) shows a first-generation
cephalosporin with a small side-chain inside the active site of
TEM-l p-lacIal1lase. The ~-I;Jctam bond is positioned near the
water molecule to facilitate efficient hydrolysis. If one rtied to
put cefotaxime in this active site, it would nOt fit becau e the
rigid omeg.t loop restricts the izc ofthe cavity. Wh t happen.
then. when TEM-l murat • e.g. point mutation (. rginine
for serine) in residue 164? he I' ult i an extended spectrum
P-I ctamase (TEM-12), with slighcly increased re isrance to
cero xime and greater resistance to cefmridimc and aztreo-
nam. As you caD see in Tabl 2. TEM-12 is a very weak
extended-spectnltn p-lacramase. If. ho\ ever, a second muta-
rion occur.; (1y~inc for glm m.ue ,t position 104 yielding
TEM-26), the hydrolysi rate of ceft:tzidil1lc and rcsist.1I1 c t
cefrazidime increase greatly. The first mutation rr M-12)
1 osened up the omega 10 p. making it floppy (Figure SA). a
a cephaJosporin with • L1rge side-c11.1in, in this case
cefcazidime, can rhen fir in the active s.ite. However, the end
of the side-chain has opposing magnets on tWO sid '5, i.e. ti,e
hydroxyl groups of E140 and £240. As a result. the ceftazidillle
m h:cule is scillaring. Perfonning brain surgery on 3. III ving
patienr is Dot effi iem. TEM-26 p se es a second mutation
(Figure SB) in which Iy ine i replaced f~uramjne. Lysine is
longer molecule so It selS closer to the end of the side-chain
of ceftazidil1le. and more import:ultly, it is positively harged
pemlitting it to artr.lct the negatively charged hydroxyl at the end
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Table 2 Subslrnle prohle and ammo aCid subslilullons m TEM -derived eXlended speclrum 1)-lactaOlases
Relative VmnlC Amino acid alteration
11·lactamase CTX CAZ AZT 39 104 164 205 237 238 240 265
TEM·1 001 0.Q1 0.5 Gin Glu A,g Gin Ala G1v Glu Thl
TEM·2 008 0002 02 Lys
TEM·l2 075 01 2 Ser
TEM·l0 1.6 68 10 S", Lys










Figure 6 (A) Cehazldlme m the bmdmg sile of
TEM-12 (RI64S). The b'oken Ime bel ween
E166 and N170 represents a loosened. more
flexible omega loop caused bV the R164S
mUIOllon 'ha' weakens Ihe bonding belween
R164 and N179 across 'he neck of the loop (nOI
shown in this diagram) ThiS provides moro room
for tho bulkv Subsl.tuen, of ceftazldime. NOle that
negallvelv charged Side· chains of E104 and
E240 repol Ihe ,ermlnal carboxvl of Ihe subsli-
tuenl (8) Ceftazld,me in 'he bmdl/lg site of
TEM·26 (R164S and El04K) The longer, mote
fleXible Slde-ch m 01 Ivslne bonds with Ihe
carboxyl mOletv of Ihe ceftazldllne subSllluent
providing an addl'ional anchor (from [1]).
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of the Side-chain. Come:qut:ntly, we: nO\ have hydrogen bond
holdlllg the side-chain in pillce. making for much more dlicicnt
hydrolysis of the f}-bWlIll anabiotic. TIle: s: me occurs when
lysine rcplac~ glurnmate In residue 240 producing M-IO.
WORLDWIDE DISTRIBUTION OF ~-LACTAMASES
This ~equence of t:vents from TEM-I to TEM-12 t T M-26
or TEM-11J h, been b e:rved in other place [13]. However.
the:re are • MLs pt:culiar to certain COW1trie; e.g. a
carbapcllem-hydrolY1Jng mctallo l3--lactamase. IMP-I, faun I
almo.t exclUSively 111 Japan [l4J. In Argentina. where TEM-
derive I • B re r.:Jre, TX-M-2 i the mo t cOlllmon Esn
liS]. In Turkey, an ESBL called P It-I and XA-Ierived~­
lacramases arc common, but ill dlC rest of the world they arc
rare [16) What is happening in Turkey? Is it antibiotic usage
panerm? Is II the soil? Is iT me climate? Why is the
evolutionary process so different in Turkey dlan in the rest
of the world? These an: importam unanswered questions.
RESISTANCE MECHANISMS WORK IN CONCERT
For a ~-Iactam to work, iT must fir;t pass mrough the outer
rnembr ne of a Gram-negative: ba illus, traverse the periplasmi
space (which may contain ~-Iactama c.) and bind ro it'; target,
an enzyme (penicillin bincUng protein. PBP) responsible for cell
wall assembly. PBPs are protems ofrwo domains. one ofwllich
15 anchored In me cytoplasmic membrane and another
extending into the periplasnllc space. The periplasmic domain
is very Similar In tructure to ~-Iactam. e and c n, in mct
hydrolyze ~-Ia tams. However, It hydrolyzes 0 slowly thaT that
the bacteria multiply bcfore the antibiotic is dctoxified.
For [he ~-lactall1 antibiotic eeking i target each of these
steps presents a chaUengc. Bacteria caD lose the channels
(porins) [ha pennit The ~-lactam t pas, through lhe outer
membrane. thus limiting dIe rate at which the anabiotic can
entcr the peripl mic spacc [l7J. Wimin dli ~pace the p-
lactam may encounter cavenger molecules (/3-lactal11a cs) That
might detoxify it. Moreover, to meet the challenge ofnovel p-
lactams hacfecia can ch,lnge the kind of ~-klct.lmase tbat they
produce by Importing new ~-lactamase genes or by rnut. ring
mose that they already have, as ducl! ed above. They can also
nlUlate genes (promoters) that regulate the amount of ~­
Licmma c produccd or import novel PBP to wbich [he
antibiotic c nnot bind well. Some bacteria, e.g. Pseudol/lollflj
1'.• can even pump out /3-1actam molecules. through an activc
efflux mechanism, before they reach their target site [18].
IN VIVO EVOLUnON OF RESISTANCE
R.csltallce of clinical Lsolates to antibiotics occurs by a variety
o mechamsms, often working in conccrt. A case in point: a
19-momh-0Id female with apia. tic anemia h. d nine bl od
isolatcs of E. roJi over a 3-month penod [191, The first isolate
was sensitive to ceftazidimc. Later isolates were highly
reSIStant. My a v. nety of molecular techmquc. it was
detemlined that they were aU the arne clone. What happened?
The first isolate, obtallled n 28 a tober, made TEM-I /3-
lactamase. A blood i olate from 6 Novembcr was resiSTant t
tetra, genta, and sulfa a well as ampi illin, probably a. a
conc:quen e of pickill~ up a mobile element. Twenty-three
dllys later, a blood isolate had a ceftazidime MI of32 Ilg/nll..
Analysi howed that m ,ddirion to producing TEM-I it
hyperproduce I . HV-I ~-Ia tamase. Not nly had the strain
imported the HV-I gene, perhap ITom a neighboring strain
of K. JJIll'lI/11ol/iae, bur it also acquired a hi~hly efficient
promoter. Roger Labia had shown that simple hyperproduc-
rion of SHY-I confcITed IlIcreased resistance to ceftniduHe
(201. Moreover, elm stram also lost a porin. whIch contributed
to ~-bctamase-medJated resistance by lowing the r:.Ite of entry
of~-h1etam into the periplasm. ince active site mut.ltions tcnd
to dimini h the cat:llytic efficiency of me parent ~-Iactamase.
conditions were then ripe for election of a mutant of HV- I.
FinaUy, a highly resistant blood isoklte of E. ClJIi produced a
novel extended-spectrUlJI ~-Iactamase, ttrlned SHV8. The
dulrl eventually died with tim infection. This ase illUSTrates
that the pro e~ c. f. election of resistance are interdcpendelll
and cooperative.
CONCLUSIONS
One problem begets anomer. Increased use of one drug may
sele t particular mut.lO ns and increased use of . nothcr will
select others. As Ann UmllleTli phrased it, .All r~~sistance is loc31'.
We marvel t the f: ct tb. I me p. nuh strain ofpcni iIlin re. ist: fl[
pneumococcus migrated to lcd. nd and hio. However, I
suspect emerging resistauce develops more often locally, when
bactena are exp sed to the. Ille kinds of antibiotic under the
me kinds of conditions. There is nly one certainry regarding
gl bal di tribution. If;) new antibiotic i developed, we can be
certain that it is going to spread worldwid . I .111 not sure we an
s, y lhe same about the hacteria.
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